PB2122 VELCADITO. A PHASE II TRIAL WITH LOW DOSES OF BORTEZOMIB PLUS MELPHALAN AND PREDNISONE FOR ELDERLY PATIENTS (>75Y) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

Autor:	R. Diez Angulo, I. Oiartzabal Ormategui, D. Robles de Castro, A. Vega González de Viñaspre, L. Cuevas Palomares, E. Pérez Persona, J. M. Guinea de Castro, M. Gabilondo Jalón, A. Unamunzaga Cilaurren, G. A. Mendez Navarro, I. M. Parra Salinas, C. Pisón Herrero, A. Santamaria Lopez, C. de Miguel Sánchez
Rok vydání:	2019
Předmět:	Oncology Melphalan medicine.medical_specialty Bortezomib business.industry Low dose Hematology Newly diagnosed medicine.disease Prednisone Internal medicine medicine business Multiple myeloma medicine.drug
Zdroj:	HemaSphere. 3:955-956
ISSN:	2572-9241
DOI:	10.1097/01.hs9.0000566972.54896.74
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d0ecfe23e09947a2109df936e6b94c60 https://doi.org/10.1097/01.hs9.0000566972.54896.74 Zobrazit plný text záznamu Plný text